Talk:Canagliflozin

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Canagliflozin.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Wiki Education Foundation-supported course assignment

This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): JMatt5, Jknguye6, Tnguy1081, Nikki9308.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 16:38, 16 January 2022 (UTC)[reply]

Article is unbalanced

This article is very unbalanced. It is very strange for an article like this to devote almost 3/4 of the text to potential side effects, while hardly even mentioning any potential benefits. It clearly must have a positive risk/benefit ratio because it has been approved by the FDA for treatment of type II diabetes, but the article is skewed to make the reader think otherwise. Moretto (talk) 20:11, 29 March 2013 (UTC)[reply]

Added a bit about benefits. The side effects section is still somewhat misleading as it uses primary sources and what J&J told investors, which often isn't really relevant medically. --ἀνυπόδητος (talk) 12:55, 2 March 2014 (UTC)[reply]

Contraindications Section is incorrect.

The sodium-glucose transport protein inhibitor canagliflozin does not become ineffective with type I diabetes nor is there a reason it should. There are likely numerous reasons the USFDA hasn't approved it for type I treatment but the fact remains that it is quite effective in type 1 treatment. Many endocrinologists have already begun prescribing it with great success. — Preceding unsigned comment added by Slartimacfast (talk • contribs) 23:13, 30 September 2014 (UTC)[reply]

A reference is needed for that. Doc James (talk · contribs · email) 19:06, 16 April 2019 (UTC)[reply]

What text in the source supports the text in question?

Added "Other sources recommend Canagliflozin as a preferred treatment for those not adequately controlled on metformin." with 3 references. Physicians have differing opinions and I thought it right to include both.Daveburstein (talk) 23:58, 15 April 2019 (UTC)[reply]

"Other sources recommend Canagliflozin as a preferred treatment for those not adequately controlled on metformin.^[1]^[2]"

The ref does not even mention canagliflozin? Doc James (talk · contribs · email) 19:06, 16 April 2019 (UTC)[reply]

References

^ Lee G, Oh SW, Hwang SS, Yoon JW, Kang S, Joh HK, Kwon H, Kim J, Park D (2017-05-25). "Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis". PLOS ONE. 12 (5): e0177646. Bibcode:2017PLoSO..1277646L. doi:10.1371/journal.pone.0177646. PMC 5444626. PMID 28542373.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ "Medscape Log In". login.medscape.com. Retrieved 2019-04-15.

As a longevity drug

"Canagliflozin (Cana), a clinically important anti-diabetes drug, leads to a 14% increase in median lifespan and a 9% increase in the 90th percentile age when given to genetically heterogeneous male mice from 7 months of age, but does not increase lifespan in female mice. Canagliflozin retards age-related lesions in heart, kidney, liver, and ... pubmed.ncbi.nlm.nih.gov/35974129/ pubmed.ncbi.nlm.nih.gov/35974129/" Should this be mentioned at text? — Preceding unsigned comment added by Treonsverdery (talk • contribs) 22:43, 8 March 2024 (UTC)[reply]

[1] Lee G, Oh SW, Hwang SS, Yoon JW, Kang S, Joh HK, Kwon H, Kim J, Park D (2017-05-25). "Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis". PLOS ONE. 12 (5): e0177646. Bibcode:2017PLoSO..1277646L. doi:10.1371/journal.pone.0177646. PMC 5444626. PMID 28542373.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[2] "Medscape Log In". login.medscape.com. Retrieved 2019-04-15.

[1]

[2]